Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation

被引:1
|
作者
Tourne, Morgan [1 ]
Tauziede-Espariat, Arnault [1 ]
Dezamis, Edouard [2 ]
Saffroy, Raphael [3 ]
Dhermain, Frederic [4 ]
Chretien, Fabrice [1 ]
Varlet, Pascale [1 ]
机构
[1] Descartes Univ, St Anne Hosp, Dept Neuropathol, Paris, France
[2] Descartes Univ, St Anne Hosp, Dept Neurosurg, Paris, France
[3] Hop Univ Paris Sud, Hop Paul Brousse, AP HP, Dept Biochem & Oncogenet, Villejuif, France
[4] Gustave Roussy Canc Campus, Dept Radiat Oncol, Villejuif, France
关键词
Anaplastic astrocytoma; BRAF V600E; Collision tumour; IDH1; mutation; Pleomorphic xanthoastrocytoma; COLLISION TUMOR; MENINGIOMA; DIFFERENTIATION; FEATURES; GLIOMAS; BRAIN;
D O I
10.1016/j.wneu.2018.05.156
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Collision tumors are often difficult to distinguish from intratumoral heterogeneity in diffuse gliomas. CASE DESCRIPTION: We report the case of a 44-year-old woman admitted for intracranial hypertension. Magnetic resonance imaging revealed a right intra-axial frontal mass, composed of a hypervascular nodular portion contrasting with a large nonenhanced infiltrative and muliticystic portion. Histopathologic examination showed the occurrence of two morphologically different gliomas. The largest component corresponded to an anaplastic astrocytoma, IDH1-mutated. The second corresponded to a leptomeningeal nodule, reminiscent of a pleomorphic xanthoastrocytoma. Both tumoral components exhibited anaplastic features, World Health Organization grade III. Immunohistochemical and molecular studies showed that the 2 components were identical, IDH1 R132H mutated but without BRAF V600E mutation. Tumor progression was assessed 2 years after surgery, after radiotherapy and chemotherapy, showing supratentorial leptomeningeal dissemination. CONCLUSIONS: Collision tumors and combined neoplasms have been rarely described in the brain and only 4 similar articles report the synchronous occurrence of 2 primary gliomas. A review of the literature is proposed, focusing on criteria that could be used to discriminate them.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 50 条
  • [31] Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation
    Zhu, Jian
    Cui, Gang
    Chen, Ming
    Xu, Qinian
    Wang, Xiuyun
    Zhou, Dai
    Lv, Shengxiang
    Fu, Linshan
    Wang, Zhong
    Zuo, Jianling
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2013, 50 (01) : 165 - 171
  • [32] Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
    Olar, Adriana
    Raghunathan, Aditya
    Albarracin, Constance T.
    Aldape, Kenneth D.
    Cahill, Daniel P., III
    Powell, Suzanne Z.
    Goodman, J. Clay
    Fuller, Gregory N.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2012, 16 (03) : 161 - 170
  • [33] Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status
    Ohno, Makoto
    Narita, Yoshitaka
    Miyakita, Yasuji
    Okita, Yoshiko
    Matsushita, Yuko
    Yoshida, Akihiko
    Fukushima, Shintaro
    Ichimura, Koichi
    Kayama, Takamasa
    Shibui, Soichiro
    BRAIN TUMOR PATHOLOGY, 2012, 29 (04) : 183 - 191
  • [34] Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens
    Preusser, Matthias
    Woehrer, Adelheid
    Stary, Susanne
    Hoeftberger, Romana
    Streubel, Berthold
    Hainfellner, Johannes A.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2011, 70 (08) : 715 - 723
  • [35] Segregation of Non-p.R132H Mutations in IDH1 in Distinct Molecular Subtypes of Glioma
    Gravendeel, Lonneke A. M.
    Kloosterhof, Nanne K.
    Bralten, Linda B. C.
    van Marion, Ronald
    Dubbink, Hendrikus Jan
    Dinjens, Winand
    Bleeker, Fonnet E.
    Hoogenraad, Casper C.
    Michiels, Erna
    Kros, Johan M.
    van den Bent, Martin
    Smitt, Peter A. E. Sillevis
    French, Pim J.
    HUMAN MUTATION, 2010, 31 (03) : E1186 - E1199
  • [36] Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype
    Salem, Dalia
    Abd El-Aziz, Sherin
    El-Menshawy, Nadia
    Abouzeid, Tarek
    Ebrahim, Mohamed
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 49 - 55
  • [37] ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
    Reuss, David E.
    Sahm, Felix
    Schrimpf, Daniel
    Wiestler, Benedikt
    Capper, David
    Koelsche, Christian
    Schweizer, Leonille
    Korshunov, Andrey
    Jones, David T. W.
    Hovestadt, Volker
    Mittelbronn, Michel
    Schittenhelm, Jens
    Herold-Mende, Christel
    Unterberg, Andreas
    Platten, Michael
    Weller, Michael
    Wick, Wolfgang
    Pfister, Stefan M.
    von Deimling, Andreas
    ACTA NEUROPATHOLOGICA, 2015, 129 (01) : 133 - 146
  • [38] Oligodendroglioma showing pleomorphic xanthoastrocytoma-like perivascular microlesion: With IDH1, TERT promoter mutation and 1p/19q codeletion detected in both components
    Murakami, Chiaki
    Ikota, Hayato
    Nobusawa, Sumihito
    Nakata, Satoshi
    Yamazaki, Tatsuya
    Hashiba, Yasuhiro
    Hirato, Junko
    Yokoo, Hideaki
    PATHOLOGY INTERNATIONAL, 2020, 70 (01) : 40 - 46
  • [39] IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas
    Fujita, Yoko
    Nunez-Rubiano, Luis
    Dono, Antonio
    Bellman, Allison
    Shah, Mauli
    Rodriguez, Juan C.
    Putluri, Vasanta
    Kamal, Abu Hena Mostafa
    Putluri, Nagireddy
    Riascos, Roy F.
    Zhu, Jay-Jiguang
    Esquenazi, Yoshua
    Ballester, Leomar Y.
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (02) : 261 - 270
  • [40] IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas
    Yoko Fujita
    Luis Nunez-Rubiano
    Antonio Dono
    Allison Bellman
    Mauli Shah
    Juan C. Rodriguez
    Vasanta Putluri
    Abu Hena Mostafa Kamal
    Nagireddy Putluri
    Roy F. Riascos
    Jay-Jiguang Zhu
    Yoshua Esquenazi
    Leomar Y. Ballester
    Journal of Neuro-Oncology, 2022, 159 : 261 - 270